AQST insider transaction filings
Aquestive Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-16. Screen AQST transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 9 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 6 legs across 5 filings by 3 insiders — 108,750 shares, $498,914 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 11.
- Largest priced transaction: sale of 25,000 shares @ $5.02 ($125,392) by Krop Julie, filed 2026-06-24.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Barber Daniel — President and CEO, Director | 4 | — | 4 legs · 75,000 sh · $327,847 | 2 |
| Krop Julie — Director | 1 | — | 1 leg · 25,000 sh · $125,392 | 2 |
| Korczynski Sherry — Chief Commercial Officer | 2 | — | 1 leg · 8,750 sh · $45,675 | 3 |
| Boyd Peter E. — Chief People Officer | 1 | — | — | 2 |
| Jung Cassie — Chief Operating Officer | 1 | — | — | 2 |
Recent Form 4 filings — Aquestive Therapeutics, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-16 | 4 | Barber Daniel — President and CEO, Director | Sale (S): 25,000 @ $4.82 | EDGAR |
| 2026-09-11 | 4 | Korczynski Sherry — Chief Commercial Officer | Option exercise (M): 8,750 @ $2.65 · Sale (S): 8,750 @ $5.22 · Option exercise (M): 8,750 (derivative) @ $0 | EDGAR |
| 2026-09-10 | 4 | Boyd Peter E. — Chief People Officer | Option exercise/expiry (X): 2,293 @ $0.96 · Option exercise/expiry (X): 2,293 (derivative) @ $0 | EDGAR |
| 2026-09-09 | 4 | Barber Daniel — President and CEO, Director | Option exercise/expiry (X): 91,743 @ $0.96 · Option exercise/expiry (X): 91,743 (derivative) @ $0 | EDGAR |
| 2026-09-08 | 4 | Jung Cassie — Chief Operating Officer | Option exercise/expiry (X): 4,587 @ $0.96 · Option exercise/expiry (X): 4,587 (derivative) @ $0 | EDGAR |
| 2026-08-18 | 4 | Barber Daniel — President and CEO, Director | Sale (S): 25,000 @ $4.29 | EDGAR |
| 2026-08-17 | 4 | Korczynski Sherry — Chief Commercial Officer | Tax withholding (F): 2,714 @ $4.25 | EDGAR |
| 2026-07-17 | 4 | Barber Daniel — President and CEO | Sale (S): 4,631 @ $4.03 · Sale (S): 20,369 @ $4.00 | EDGAR |
| 2026-06-24 | 4 | Krop Julie — Director | Option exercise (M): 25,000 @ $0.71 · Sale (S): 25,000 @ $5.02 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Barber Daniel — President and CEO | Sale (S): 25,000 @ $4.16 | EDGAR |
| 2026-06-12 | 4 | Krop Julie — Director | Grant/award (A): 50,500 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Jenkins Abigail L. — Director | Grant/award (A): 50,500 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Cochran John — Director | Grant/award (A): 50,500 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Taglietti Marco — Director | Grant/award (A): 50,500 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | BROWN GREGORY B — Director | Grant/award (A): 50,500 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | MORRIS TIMOTHY E — Director | Grant/award (A): 50,500 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Korczynski Sherry — Chief Commercial Officer | Tax withholding (F): 2,714 @ $0 | EDGAR |
| 2026-05-19 | 4 | Zalewski Thomas A. — Chief Legal Officer | Grant/award (A): 100,000 @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Barber Daniel — President and CEO | Sale (S): 8,257 @ $4.29 | EDGAR |
| 2026-05-18 | 4 | Cioffi Melina — SVP, Regulatory Affairs | Tax withholding (F): 1,667 @ $4.17 | EDGAR |
| 2026-05-11 | 4 | BRAENDER LORI J — Corporate Secretary | Tax withholding (F): 135,690 @ $4.23 | EDGAR |
| 2026-05-07 | 4 | Boyd Peter E. — Chief People Officer | Tax withholding (F): 56,778 @ $4.18 | EDGAR |
| 2026-05-07 | 4 | Barber Daniel — President and CEO | Tax withholding (F): 335,922 @ $4.18 | EDGAR |
| 2026-05-07 | 4 | Jung Cassie — Chief Operating Officer | Tax withholding (F): 72,734 @ $4.18 | EDGAR |
| 2026-05-07 | 4 | BRAENDER LORI J — Corporate Secretary | Tax withholding (F): 76,147 @ $4.18 | EDGAR |
| 2026-05-07 | 4 | TOTH A ERNEST JR — Chief Financial Officer | Tax withholding (F): 92,652 @ $4.18 | EDGAR |
| 2026-04-13 | 4 | Barber Daniel — President and CEO | Grant/award (A): 293,100 (derivative) @ $0 | EDGAR |
| 2026-04-13 | 4 | Boyd Peter E. — Chief People Officer | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-04-13 | 4 | Jung Cassie — Chief Operating Officer | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2026-04-13 | 4 | Korczynski Sherry — Chief Commercial Officer | Grant/award (A): 67,500 (derivative) @ $0 | EDGAR |
| 2026-04-13 | 4 | BRAENDER LORI J — Corporate Secretary | Grant/award (A): 82,500 (derivative) @ $0 | EDGAR |
| 2026-04-13 | 4 | TOTH A ERNEST JR — SVP, Chief Financial Officer | Grant/award (A): 82,500 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Boyd Peter E. — Chief People Officer | Grant/award (A): 80,000 @ $0 · Sale (S): 29,814 @ $4.17 · Grant/award (A): 42,500 (derivative) @ $4.29 | EDGAR |
| 2026-03-11 | 4 | Barber Daniel — President and CEO | Grant/award (A): 262,000 @ $0 · Sale (S): 180,677 @ $4.17 · Grant/award (A): 523,000 (derivative) @ $4.29 | EDGAR |
| 2026-03-11 | 4 | BRAENDER LORI J — Chief Legal Officer | Grant/award (A): 80,000 @ $0 · Sale (S): 40,102 @ $4.17 · Grant/award (A): 50,000 (derivative) @ $4.29 | EDGAR |
| 2026-03-11 | 4 | Cioffi Melina — SVP, Regulatory Affairs | Grant/award (A): 100,000 @ $0 · Sale (S): 25,311 @ $4.17 · Grant/award (A): 75,000 (derivative) @ $4.29 | EDGAR |
| 2026-03-11 | 4 | Korczynski Sherry — Chief Commercial Officer | Grant/award (A): 75,000 @ $0 · Sale (S): 15,741 @ $4.17 · Grant/award (A): 42,500 (derivative) @ $4.29 | EDGAR |
| 2026-03-11 | 4 | Jung Cassie — Chief Operating Officer | Grant/award (A): 80,000 @ $0 · Sale (S): 45,791 @ $4.17 · Grant/award (A): 42,500 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Davis Matthew W. — Chief Development Officer | Grant/award (A): 50,000 @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Greenhawt Matthew J. — Chief Medical Officer | Grant/award (A): 75,000 @ $0 · Grant/award (A): 50,000 (derivative) @ $4.29 | EDGAR |
| 2026-03-11 | 4 | TOTH A ERNEST JR — Chief Financial Officer | Grant/award (A): 95,000 @ $0 · Sale (S): 58,254 @ $4.17 · Grant/award (A): 70,000 (derivative) @ $0 | EDGAR |
| 2025-12-05 | 4 | Boyd Peter E. — Chief People Officer | Grant/award (A): 20,000 @ $0 | EDGAR |
| 2025-12-04 | 4 | Cioffi Melina — SVP, Regulatory Affairs | Tax withholding (F): 2,083 @ $5.93 | EDGAR |
| 2025-11-12 | 4 | Davis Matthew W. — Chief Development Officer | Grant/award (A): 50,000 @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2025-10-17 | 4 | Jung Cassie — Chief Operating Officer | Option exercise (M): 25,000 @ $3.10 · Sale (S): 67,575 @ $7.01 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2025-10-17 | 4 | Kraus Carl N — Chief Medical Officer | Sale (S): 20,272 @ $7 | EDGAR |
| 2025-10-17 | 4 | Boyd Peter E. — See Remarks | Sale (S): 10,000 @ $7 | EDGAR |
| 2025-09-29 | 4 | Barber Daniel — President and CEO, Director | Sale (S): 91,343 @ $6.03 | EDGAR |
| 2025-09-29 | 4 | Boyd Peter E. — See Remarks | Sale (S): 10,000 @ $6.30 | EDGAR |
| 2025-09-22 | 4 | Barber Daniel — President and CEO, Director | Sale (S): 400 @ $6 | EDGAR |
Recent 8-K events — Aquestive Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-17 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-20 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-02 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AQST returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →